Industry NewsLife Sciences Ten-year APHINITY data show Roche’s Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer
Product NewsClinical Diagnostics Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer
